Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
1. Introduction - p. xi 2. Chapter 1: Angiogenesis and Anti-Angiogenesis Strategies in Cancer - p. xv 3. Chapter 2: Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques - p. 19 4. Chapter 3: Anti-Angiogenesis in Multiple Myeloma - p. 38 5. Chapter 4: Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression - p. 50 6. Chapter 5: microRNAs and Angiogenesis - p. 68 7. Chapter 6: Naturally Occurring Angiogenesis Inhibitors - p. 84 8. Chapter 7: Integrin Antagonists and Angiogenesis - p. 97 9. Chapter 8: Tyrosine Kinase Inhibitors and Angiogenesis - p. 123 10. Chapter 9: Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis - p. 131 11. Chapter 10: Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis - p. 146 12. Chapter 11: Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics - p. 163 13. Chapter 12: New Directions in Anti-Angiogenesis Research - p. 178 14. Index - p. 186
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
1. Introduction - p. xi 2. Chapter 1: Angiogenesis and Anti-Angiogenesis Strategies in Cancer - p. xv 3. Chapter 2: Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques - p. 19 4. Chapter 3: Anti-Angiogenesis in Multiple Myeloma - p. 38 5. Chapter 4: Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression - p. 50 6. Chapter 5: microRNAs and Angiogenesis - p. 68 7. Chapter 6: Naturally Occurring Angiogenesis Inhibitors - p. 84 8. Chapter 7: Integrin Antagonists and Angiogenesis - p. 97 9. Chapter 8: Tyrosine Kinase Inhibitors and Angiogenesis - p. 123 10. Chapter 9: Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis - p. 131 11. Chapter 10: Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis - p. 146 12. Chapter 11: Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics - p. 163 13. Chapter 12: New Directions in Anti-Angiogenesis Research - p. 178 14. Index - p. 186
